Innate Pharma S.A. (IPHA)

NASDAQ: IPHA · USD

$1.33

-0.07 (-5.0%)· Recorded snapshot

Market cap	125.2M
Revenue (ttm)	11.2M
Net income (ttm)	-54.2M
EPS (ttm)	-$0.57
Shares out	93.7M
P/E (forward)	27.3x
Volume	69,328.333
Beta	1.19

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 11.2M
Net income (ttm): -54.2M
EPS (ttm): -$0.57
P/E (forward): 27.3x
Market cap: 125.2M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Halten

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-11-04 14:30 UTC

Forward P/E27.3

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROEn/a

P25 -113.8P50 -46.5P75 -0.9

ROIC-2,545.1

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All IPHA indicators

Market & fundamental data

Available fields

192

Groups with data

Currency

EUR

Showing 192 of 192 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001598599
Company name	Innate Pharma S.A.
Country	France
Country code	US
CUSIP number	45781K204
Earnings date	2026-09-17
Earnings time	bmo
Employees	120
Employees change	-44
Employees growth	-26.83%
Enterprise value	$135.6M
Exchange	NASDAQ
Financial currency	EUR
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1999
Industry	Biotechnology
IPO date	2019-10-17
Is primary listing	No
Is SPAC	No
ISIN number	US45781K2042
Last 10-K release date	2026-04-01
Last earnings date	2026-09-17
Last refreshed	2026-11-04
Last stock split type	Never
Market cap	$125.2M
Market cap category	Micro-Cap
Next earnings date	2027-03-25
Options	No
Price	$1.33
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-11-03
Symbol	IPHA
Website	https://www.innate-pharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-43.17%
EV/Sales	12.11x
FCF / EV yield	-35.53%
FCF yield	-38.48%
Forward EV/Sales	12.7x
Forward P/E	27.28x
Forward P/S	11.73x
P/S ratio	11.18x
Sector forward P/E	24x
Sector P/E	49.18x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Operating margin	-485.25%
Pretax margin	-483.85%
Profit per employee	$-451,807
Revenue per employee	$93,378
ROA	-46.6%
ROA (5Y)	-16.08%
ROCE	-2,545.08%
ROIC	-2,545.08%
SBC / revenue	21.25%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	1
Net income growth years	1
Revenue growth	-22.38%
Revenue growth (Q)	16.52%
Revenue growth (QoQ)	36.62%
Revenue growth 10Y	-11.47%
Revenue growth 3Y	-42.75%
Revenue growth 5Y	-29.93%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-193,629
Depreciation and amortization	$710,347
EBIT	$-54.4M
EBITDA	$-53.7M
EPS	$-0.57
FCF per share	$-0.51
Financing cash flow	$-7.7M
Free cash flow	$-48.2M
Free cash flow minus SBC	$-50.5M
Gross profit	$-34.5M
Investing cash flow	$2.7M
Net borrowing	$-7.7M
Net cash flow	$-54M
Net income	$-54.2M
Operating cash flow minus SBC	$-50.3M
Operating income	$-54.4M
Revenue	$11.2M
Stock-based compensation	$2.4M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-21.88
Book value per share	$-0.49
Interest coverage	-124.92
Long-term assets	$17.6M
Long-term liabilities	$49M
Net cash (debt)	$-10.6M
Net cash / market cap	-8.49%
Piotroski F-Score	3
Property, plant and equipment	$4.1M
Shareholders' equity	$-46.3M
Tangible book value	$-46.3M
Tangible book value per share	$-0.49
Total assets	$39.7M
Total cash	$12.4M
Total debt	$23.1M
Total liabilities	$86M
WACC	9.34%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.15
Current assets	$22.1M
Current liabilities	$37M
Current ratio	0.6
Net working capital	$-15.3M
Quick ratio	0.47
Working capital	$-15.1M
Working capital turnover	0.37

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-10.65%
Dividend yield	0%
Shareholder yield	-10.65%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$1.75
1D price change	-5%
1M price change	-14.74%
1M total return	-14.74%
1W price change	-10.14%
1W total return	-10.14%
1Y price change	-32.49%
1Y return CAGR	-32.51%
1Y total return	-32.49%
20-day SMA	$1.48
200-day SMA	$1.71
3M price change	-24%
3M total return	-24%
3Y price change	-40.36%
3Y return CAGR	-15.82%
3Y total return	-40.36%
50-day SMA	$1.73
50-day SMA vs 200-day SMA	50over200
52-week high	$2.71
52-week high date	2026-08-13
52-week low	$1.17
52-week low date	2026-03-20
5Y price change	-77.07%
5Y return CAGR	-25.52%
5Y total return	-77.07%
6M price change	-7.64%
6M total return	-7.64%
After-hours change	3.76%
After-hours close	$1.33
After-hours price	$1.38
All-time high	$11.95
All-time high date	2021-09-17
All-time low	$1.17
All-time low date	2026-03-20
Average true range (ATR)	$0.10
Average volume	19.6K
Beta (5Y)	1.19
Change from 52-week high	-50.92%
Change from 52-week low	13.68%
Change from all-time high	-88.87%
Change from all-time low	13.68%
Change from open	-1.48%
Day's gap	-3.57%
Dollar volume	$92,207
High price	$1.35
Low price	$1.32
Monthly RSI	40.56
Open price	$1.35
Position in 52-week range	33.33%
Premarket change	4.51%
Premarket close	$1.33
Premarket price	$1.39
Premarket volume	592
Previous close	$1.40
Price vs 150-day SMA	-23.78%
Price vs 20-day SMA	-10.32%
Price vs 200-day SMA	-22.22%
Price vs 50-day SMA	-23.17%
Relative volume	3.54
Return from IPO price	-75.82%
RSI	32.86
Sharpe ratio	-0.03
Sharpe ratio (3Y)	0.15
Sharpe ratio (5Y)	0.02
Sortino ratio	0.03
Sortino ratio (3Y)	0.4
Sortino ratio (5Y)	0.13
Volume	69.3K
Weekly RSI	37.35
YTD price change	-24%
YTD total return	-24%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	68.9M
Float percentage	73.5%
Shares change (QoQ)	1.71%
Shares change (YoY)	10.65%
Shares held by insiders	0.74%
Shares held by institutions	6.04%
Shares outstanding	93.7M
Short % of shares	0.11%
Short ratio	2.1 days

Deeper analysis on IPHA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this IPHA report

Is a complete IPHA research report available?

No complete published report is available for Innate Pharma S.A. (IPHA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Innate Pharma S.A. (IPHA)

Price

Financial snapshot

Fair-value bridge

Latest news · IPHA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All IPHA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on IPHA

Frequently asked questions